HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Thematic (Sector/Industry)

Industry viewpoints:
<ul>
<li>Recently, the NMPA issued a new version of the regulations on the supervision and administration of medical devices.</li>
<li>In the primary market, the appetite for small CRO/CDMO investments continues to grow.</li>
<li>The market size of China's traditional Chinese medicine (TCM) devices is not large. However, under the promotion of favorable policies and demand growth , it is growing steadily.</li>
</ul>
Company news:
News about the updated progress of new drug and medical device from <a href="https://www.smartkarma.com/entities/everest-medicines-ltd" target="_blank" data-smartkarma-citation="entities:29224:1" rel="noopener">Everest Medicines (1952 HK)</a>, <a href="https://www.smartkarma.com/entities/harbour-biomed-holdings-limited" target="_blank" data-smartkarma-citation="entities:29717:1" rel="noopener">Harbour Biomed Holdings Limited (2142 HK)</a>, and <a href="https://www.smartkarma.com/entities/venus-medtech-hangzhou-inc" target="_blank" data-smartkarma-citation="entities:28257:1" rel="noopener">Venus MedTech (2500 HK).</a>
Market review:
Last week, stock price for healthcare sector in A share increased 3.25%, while CSI 300 increased 0.62% over the same period of time. 
Risk disclosure:
Policy risk, R&amp;D risk, Company risk and COVID-19 risk.

Industry viewpoints:

Recently, the NMPA issued a new version of the regulations on the supervision and administration of medical devices.
In the primary market, the appetite for small CRO/CDMO investments continues to grow.
The market size of China's traditional Chinese medicine (TCM) devices is not large. However, under the promotion of favorable policies and demand growth , it is growing steadily.

Company news:
News about the updated progress of new drug and medical device from Everest Medicines (1952 HK), Harbour Biomed Holdings Limited (2142 HK), and Venus MedTech (2500 HK).
Market review:
Last week, stock price for healthcare sector in A share increased 3.25%, while CSI 300 increased 0.62% over the same period of time. 
Risk disclosure:
Policy risk, R&amp;D risk, Company risk and COVID-19 risk.

1. Industry viewpoints:<ul>
<li>An important document supporting the development of the traditional Chinese medicine industry has been released recently.</li>
<li>The market size of cardiac pacemakers in China is expected to reach RMB28 billion in the future.</li>
<li>China's health care products market is expected to maintain rapid growth in the future. </li>
</ul>2. Company news:News about the progress of new drugs and strategic collaboration from <a href="https://www.smartkarma.com/entities/innovent-biologics-inc" target="_blank" data-smartkarma-citation="entities:27452:1" rel="noopener">Innovent Biologics Inc (1801 HK)</a>, <a href="https://www.smartkarma.com/entities/sihuan-pharmaceutical-hldgs" target="_blank" data-smartkarma-citation="entities:33:1" rel="noopener">Sihuan Pharmaceutical Hldgs (460 HK)</a> and <a href="https://www.smartkarma.com/entities/jiangsu-hengrui-medicine-co-ltd" target="_blank" data-smartkarma-citation="entities:14128:1" rel="noopener">Jiangsu Hengrui Medicine (600276 CH).</a>3. Market review:Last week, stock price for healthcare sector in A share increased 6.31%, while CSI 300 increased 5.91% over the same period of time.4. Risk disclosure:Policy risk, R&amp;D risk, Company risk and COVID-19 risk.

1. Industry viewpoints:
An important document supporting the development of the traditional Chinese medicine industry has been released recently.
The market size of cardiac pacemakers in China is expected to reach RMB28 billion in the future.
China's health care products market is expected to maintain rapid growth in the future. 
2. Company news:News about the progress of new drugs and strategic collaboration from Innovent Biologics Inc (1801 HK), Sihuan Pharmaceutical Hldgs (460 HK) and Jiangsu Hengrui Medicine (600276 CH).3. Market review:Last week, stock price for healthcare sector in A share increased 6.31%, while CSI 300 increased 5.91% over the same period of time.4. Risk disclosure:Policy risk, R&amp;D risk, Company risk and COVID-19 risk.

Chine Healthcare Weekly(Feb12)-TCM New Policy,Cardiac Pacemaker,Health Care Product,Innovent,Hengrui

1. Industry viewpoints:<ul>
<li>With the aggravation of aging, the number of stroke patients would grow rapidly and it is estimated that the potential market size of neurointerventional medical devices would reach RMB33.3 billion in 2025</li>
<li>China has a huge demographic dividend and demand for vision correction. It is expected to be a large growth space for orthokeratology lenses industry in China.</li>
<li>Pet medical industry started late in China, but it develops rapidly.</li>
</ul>2. Company news:News about the progress of new drugs of <a href="https://www.smartkarma.com/entities/everest-medicines" target="_blank" data-smartkarma-citation="entities:29224:1" rel="noopener">Everest Medicines (1952 HK)</a>, <a href="https://www.smartkarma.com/entities/antengene-corporation-limited" target="_blank" data-smartkarma-citation="entities:29705:1" rel="noopener">Antengene (6996 HK)</a> and <a href="https://www.smartkarma.com/entities/jacobio-pharmaceuticals" target="_blank" data-smartkarma-citation="entities:29696:1" rel="noopener">Jacobio Pharmaceuticals (1167 HK)</a>.3. Market review:Last week, stock price for healthcare sector in A share increased 2.88%, while CSI 300 increased 5.45% over the same period of time.4. Risk Disclosure:Policy risk, R&amp;D risk, Company risk and COVID-19 risk.

1. Industry viewpoints:
With the aggravation of aging, the number of stroke patients would grow rapidly and it is estimated that the potential market size of neurointerventional medical devices would reach RMB33.3 billion in 2025
China has a huge demographic dividend and demand for vision correction. It is expected to be a large growth space for orthokeratology lenses industry in China.
Pet medical industry started late in China, but it develops rapidly.
2. Company news:News about the progress of new drugs of Everest Medicines (1952 HK), Antengene (6996 HK) and Jacobio Pharmaceuticals (1167 HK).3. Market review:Last week, stock price for healthcare sector in A share increased 2.88%, while CSI 300 increased 5.45% over the same period of time.4. Risk Disclosure:Policy risk, R&amp;D risk, Company risk and COVID-19 risk.

On October 16, 2020, the government released a new policy for the intensive procurement of coronary stents, which kicked off the nationwide intensive procurement for high-value medical consumables. According to the policy, The amount of coronary stents purchased in the first year was around 1,074,000, accounting for about 70% of the national annual consumption of coronary stents. The results of this policy have a strong reference for the future expansion of high-value medical consumables' intensive procurement. On November 5, the policy was formally implemented and the result was released.

On October 16, 2020, the government released a new policy for the intensive procurement of coronary stents, which kicked off the nationwide intensive procurement for high-value medical consumables. According to the policy, The amount of coronary stents purchased in the first year was around 1,074,000, accounting for about 70% of the national annual consumption of coronary stents. The results of this policy have a strong reference for the future expansion of high-value medical consumables' intensive procurement. On November 5, the policy was formally implemented and the result was released.

Insights on China Healthcare Policy: New Intensive Procurement Policy for High-Value Medical Devices

1. Industry viewpoints: <ul>
<li>China’s new intensive procurement policy has finally been applied to high-value medical consumables. Thus, related medical device companies are facing new challenges.</li>
<li>
With the increase of patients' affordability and doctors' cognition and acceptance of minimally invasive surgery, it is expected that MISIA market will have greater growth potential in the near future. 
</li>
<li>In recent years, China cancer drug market has grown rapidly. With large growth potential in this market and more favorable policy, more innovative cancer drugs will be approved in China</li>
</ul>2. Company newsNews of Jiangsu Hengrui Medicine, Dingdang Kuaiyao and AstraZeneca China on the cooperation of new drugs and the progress of new funding.3. Market reviewLast week, stock price for healthcare sector in A share decreased 6.24%, while CSI 300 decreased 1.53% over the same period of time.

1. Industry viewpoints: 
China’s new intensive procurement policy has finally been applied to high-value medical consumables. Thus, related medical device companies are facing new challenges.

With the increase of patients' affordability and doctors' cognition and acceptance of minimally invasive surgery, it is expected that MISIA market will have greater growth potential in the near future. 

In recent years, China cancer drug market has grown rapidly. With large growth potential in this market and more favorable policy, more innovative cancer drugs will be approved in China
2. Company newsNews of Jiangsu Hengrui Medicine, Dingdang Kuaiyao and AstraZeneca China on the cooperation of new drugs and the progress of new funding.3. Market reviewLast week, stock price for healthcare sector in A share decreased 6.24%, while CSI 300 decreased 1.53% over the same period of time.

China

MicroPort Scientific is a leading global medical device company that innovates, manufactures, and markets high-end medical devices. The company provides solutions across twelve therapeutic areas, including cardiovascular, orthopedics, cardiac rhythm management, electrophysiology, endovascular, neurovascular, and surgical robotics. It was founded in 1998 and is headquartered in Shanghai, China.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

MicroPort Scientific (853 HK)

China Healthcare Weekly (Mar.26)

The article analyzed healthcare industry viewpoints include a new version of regulations on medical devices, the CRO/CDMO industry, China TCM...

Xinyao (Criss) Wang

Chine Healthcare Weekly(Feb12)-TCM New Policy,Cardiac Pacemaker,Health Care Product,Innovent,Hengrui

This article analyzed industry viewpoints include new policy about traditional Chinese medicine, cardiac pacemakers market, health care products...

Xinyao (Criss) Wang

China Healthcare Weekly (Jan.8)

The article analyzed the viewpoints in neurointerventional medical devices market, orthokeratology lenses market and pet medical market in China,...

Xinyao (Criss) Wang

Insights on China Healthcare Policy: New Intensive Procurement Policy for High-Value Medical Devices

The article analyzed potential impact of China's new intensive procurement policy on high-value medical devices. If interested in investing China...

Xinyao (Criss) Wang

China Healthcare Weekly (Oct.23)

This article summarized important new China healthcare policy released last week, major industry viewpoints, company news and market review for...

Xinyao (Criss) Wang

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)